Search Results
Apr 29, 2026, 08:56 ET NanoMosaic to Showcase the FDA/CBER AMT Designated Analytics Platform at ASGCT 2026
quantificationDate/Time: 5/14/2026, 5:00PM-6:30PMNanoMosaic Poster 1 launching the RNA quantification assay on Tessie system: Poster No. 3222Title: Integrated AAV genome integrity and transgene RNA quantification using a single nanoneedle-based platformDate/Time: 5/14/2026,
More news about: NanoMosaic
Apr 29, 2026, 07:00 ET PreludeDx Receives FDA Breakthrough Device Designation for AidaBREAST® - Early-Stage Invasive Breast Cancer Assay
multi-omic assay developed by PreludeDx uses advanced spatial biology technology combining multiplex protein expression with targeted next-generation RNA sequencing to provide a comprehensive assessment of a patient's tumor biology. Leveraging the power of artificial intelligence, the assay integrates
More news about: Prelude Corporation
Apr 29, 2026, 05:00 ET Biohub Launches the Virtual Biology Initiative to Galvanize a Global Effort to Create the Open Data Foundation for AI-Accelerated Biology
particular relevance, Broad scientists have played a central role in developing single-cell analysis, including the foundational work on single-cell RNA sequencing, Perturb-Seq, optical pooled screening, various methods for spatial transcriptomics, and a range of widely-used analytical methods. Broad's
More news about: Biohub
Apr 28, 2026, 07:37 ET Arcera Life Sciences and Fosun Pharma launch long-term collaboration framework
cutting-edge biotechnology and foster sovereign R&D capabilities in the UAE across small molecules, biologics, radiopharmaceuticals, small interfering RNA therapies, and cell and gene therapies.Strategic collaboration in neuroscience: The neuroscience collaboration will focus particularly
More news about: Fosun Pharma
Apr 28, 2026, 07:00 ET Ascidian to Highlight Progress of Lead Program in Stargardt and Platform Advancements Across Therapeutic Areas at ASGCT 2026 Annual Meeting
first-ever human safety data for its lead RNA exon editing candidate, ACDN-01, from the Phase 1/2 STELLAR trial in Stargardt disease, the most common form of inherited blindness. Additionally, the company will present new data demonstrating how its AI/ML-enabled RNA discovery platform drives efficient identification
More news about: Ascidian Therapeutics
Apr 28, 2026, 07:00 ET Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
quantification of β- and α-cell mass, electron microscopy (EM), and islets were isolated for ex-vivo glucose-stimulated insulin secretion (GSIS) and single-cell RNA sequencing. The results at four weeks showed major improvements in the control of diabetes.At four weeks after surgery, ex-vivo GSIS showed that
More news about: Genprex, Inc.
Apr 27, 2026, 13:24 ET Zymo Research Launches Fecal Microbiome Discovery Grant to Enable the Next Breakthroughs in Human Health
workflows, including DNA/RNA Shield®-based collection systems for immediate nucleic acid stabilization at the point of collection, preservation kits that maintain community integrity during transport and storage, microbiome standards for accurate benchmarking, and optimized DNA and RNA extraction kits for
More news about: Zymo Research Corp.
Apr 27, 2026, 09:20 ET Ferrotec Introduces Ferrobeads® DNA/RNA Isolation Kits for High-Efficiency Nucleic Acid Extraction
Ferrobeads deliver high-purity DNA and RNA extraction in 10 to 25 minutes, depending upon whether the process is run on an automated system or manually. Ferrotec DNA/RNA Isolation kits include a lysis buffer, a wash buffer, beads and an elution buffer. Ferrotec DNA/RNA Isolation kits are available in 100
More news about: Ferrotec (USA) Corporation
Apr 27, 2026, 08:02 ET TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University
development efforts, with a focus on advancing innovative RNA-based approaches for the treatment of advanced cancers."I am honored and very much looking forward to assume this role and continue collaborating with the TransCode team to advance innovative RNA-based therapeutics targeting advanced metastatic
More news about: TransCode Therapeutics, Inc.
Apr 26, 2026, 18:40 ET Employment Law Attorneys, at Blumenthal Nordrehaug Bhowmik De Blouw LLP, Filed a Lawsuit Against Roche Molecular Systems, Inc., for Alleged Failure to Provide Required Meal Periods and Rest Periods
Roche Molecular Systems, Inc., a high-quality DNA and RNA extraction for life science applications allegedly failed to provide employees with accurate wages due to missed meals and break breaks. This allegedly resulted in violations of
More news about: Blumenthal Nordrehaug Bhowmik De Blouw LLP
Apr 26, 2026, 07:00 ET Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026
Designation.About ElebsiranElebsiran is an investigational subcutaneously administered HBV-targeting siRNA designed to degrade HBV RNA transcripts and limit the production of hepatitis B surface antigen. It has the potential to have direct antiviral activity against HBV and HDV. It is
More news about: Brii Biosciences Limited
Apr 24, 2026, 09:00 ET Circular Genomics Appoints World-Renowned Expert in Neurochemistry and Alzheimer's Fluid Biomarkers Dr. Henrik Zetterberg to Scientific Advisory Board
Leading Alzheimer's Disease Researcher Joins to Advance Circular RNA Blood-Based Biomarker Platform for Neurodegenerative DiseasesSAN DIEGO, April 24, 2026 /PRNewswire/ -- Circular Genomics, a biotechnology company
More news about: Circular Genomics
Apr 23, 2026, 08:02 ET CREATE Medicines Doses First Patient in Phase 1/2 Study of MT-304, a First-in-Class Multi-immune In Vivo CAR Therapy Targeting HER2-Positive Solid Tumors
weekend at AACR, we presented compelling preclinical data across our in vivo CAR T, CAR NK, and CAR myeloid programs, and introduced RetroT, our all-RNA genome integration platform for stable, durable cell engineering without viral vectors. Both are on track to enter the clinic within 12 months, highlighting
More news about: CREATE Medicines, Inc.
Apr 23, 2026, 08:00 ET Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone payment from
More news about: Atrium Therapeutics
Apr 23, 2026, 07:00 ET Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026
early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States,
More news about: Insmed Incorporated
Apr 23, 2026, 02:34 ET DUAL-PATHWAY BLOCKADE THERAPY OFFERS HOPE FOR RARE, HARD-TO-TREAT GYNAECOLOGICAL CLEAR CELL CANCERS
deaths were reported. Supporting these clinical findings, the bioinformatic analyses for the LARA trial were conducted at CSI Singapore. These included RNA sequencing, molecular subtyping, pathway interrogation and statistical modelling to correlate tumour biology with patient outcomes.Assoc Prof
More news about: National University Cancer Institute, Singapore (NCIS)
Apr 21, 2026, 22:10 ET Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in Neurofilament Light Chain
company focused on developing next-generation RNA-based medicines, today announced positive preliminary data from the single ascending dose (SAD) Phase I portion of its ongoing Phase I/II clinical trial of RAG-17. RAG-17 is a novel small interfering RNA (siRNA) therapeutic in development for the treatment
More news about: Ractigen Therapeutics
Apr 21, 2026, 09:11 ET ReviR Therapeutics Receives Strategic Investment from CureCMT to Advance a First-of-its-Kind Precision Medicine Platform for CMT
discovering and developing innovative therapies for patients with serious genetic diseases. ReviR was founded in 2021 by leaders in computational biology, RNA biology, genomics, and drug discovery, with the aim to create disease-modifying therapies that are highly specific, efficacious, and safe. ReviR's lead
More news about: ReviR Therapeutics
Apr 21, 2026, 06:30 ET Flagship Pioneering Launches Serif Biomedicines to Establish Modified DNA as a New Biotechnology
delivery, AI-guided DNA sequence design for cell-specific programmable gene expression, and scalable manufacturing for accessible therapeutics. Unlike RNA therapies that are limited to transient gene expression, gene therapies that cannot be redosed, and genome engineering strategies that rely on DNA integration,
More news about: Flagship Pioneering
Apr 20, 2026, 22:46 ET Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
with Nasdaq Listing Rule 5635(c)(4).About Atrium Therapeutics, Inc.Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. The Company's proprietary
More news about: Atrium Therapeutics
Apr 20, 2026, 22:10 ET Rznomics Reports Interim Clinical Data for RZ-001 in Hepatocellular Carcinoma at AACR 2026 Demonstrating Encouraging Efficacy and Favorable Safety Profile
potential of RNA trans-splicing ribozyme platform technologySEOUL, South Korea, April 20, 2026 /PRNewswire/ -- Rznomics announced today that it presented interim clinical data from its ongoing study of RZ-001, an RNA editing-based
More news about: Rznomics
Apr 20, 2026, 10:00 ET AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
SAN DIEGO, April 20, 2026 /PRNewswire/ -- Abogen, a clinical-stage biotechnology company focused on RNA innovation, today announced preliminary clinical results from the first-in-human (FIH) study of ABO2203 in patients with relapsed/refractory B-cell non-Hodgkin
More news about: Abogen
Apr 20, 2026, 10:00 ET AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
SAN DIEGO, April 20, 2026 /PRNewswire/ -- Abogen, a clinical-stage biotechnology company focused on RNA innovation, today announced preliminary clinical results from the first-in-human (FIH) study of ABO2203 in patients with relapsed/refractory B-cell non-Hodgkin
More news about: Abogen
Apr 20, 2026, 09:00 ET Eclipsebio Launches eCOMPASS™, an AI-Enabled Lab-in-the-Loop Platform for RNA Therapeutic Development
nucleotide-level information that is necessary to guide the RNA design towards optimal performance. eCOMPASS closes that gap, generating the nucleotide-level data that enable optimized RNA design."To learn more about how eCOMPASS can accelerate your RNA therapeutic program, contact
More news about: Eclipsebio
Apr 20, 2026, 08:00 ET Argo Biopharma Doses First Patients in Phase II Clinical Trials of siRNA Therapy BW-40202
April 20, 2026 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced the first patient has been dosed in multiple Phase II studies of BW-40202, an investigational siRNA therapy
More news about: Argo Biopharmaceutical Co., Ltd